首页> 外文OA文献 >Acute Myeloid Leukemia Patients with an Activating Mutation in FLT3 Respond to a Small Molecule FLT3 Tyrosine Kinase Inhibitor, PKC412

【2h】

Acute Myeloid Leukemia Patients with an Activating Mutation in FLT3 Respond to a Small Molecule FLT3 Tyrosine Kinase Inhibitor, PKC412

机译：FLT3激活突变的急性髓细胞白血病患者对小分子FLT3酪氨酸激酶抑制剂pKC412有反应

页面导航

著录项
相似文献
相关主题

著录项

作者
Richard M. Stone; Daniel J. Deangelo; Virginia Klimek; Ilene Galinsky; Eli Estey; Stephen D. Nimer; Wilson Gr; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A. Fox; Donna Neuberg; Jennifer Clark; D. Gary Gillil; James D;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 急性髓系白血病患者外周血细胞中FLT3基因表达与FLT3/ITD突变的关系及其意义 [J] . 徐兵, 史鹏程, 宋小燕, 癌症（英文版） . 2009,第006期
2. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. [J] . Fischer T, Stone RM, Deangelo DJ, Journal of Clinical Oncology . 2010,第28期

机译：IID期口服Midostaurin（PKC412），FMS样酪氨酸激酶3受体（FLT3）和多靶点激酶抑制剂的临床试验，用于患有急性髓样白血病和高危骨髓增生异常综合征的野生型或突变型FLT3患者。
3. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations [J] . AlvaradoY., KantarjianH.M., LuthraR., Cancer: A Journal of the American Cancer Society . 2014,第14期

机译：FLT3突变的急性髓性白血病患者用FLT3抑制剂的治疗与继发性FLT3-酪氨酸激酶结构域突变的发生有关
4. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia [J] . MaH.S., NguyenB., DuffieldA.S., Cancer research: The official organ of the American Association for Cancer Research, Inc . 2014,第18期

机译：FLT3激酶抑制剂TTT-3002克服了急性髓性白血病中FLT3的激活和耐药突变
5. Tandem mass spectrometry characterizes the related substances of second generation FLT3 inhibitor Quizartinib, anti cancer compound for myeloid leukemia [C] . Saravanan Subramaniyan, Arvind Thyagarajan, Rampriya Uthayakumar, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质，用于髓性白血病的抗癌化合物
6. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
7. Phase IIB Trial of Oral Midostaurin (PKC412) the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 [O] . Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo, -1

机译：患有急性髓样白血病和高危骨髓增生异常综合症（无论是野生型还是突变型FLT3）的患者口服Midostaurin（PKC412）FMS类酪氨酸激酶3受体（FLT3）和多靶点激酶抑制剂IIB期临床试验
8. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. [O] . Mead AJ, Linch DC, Hills RK, 2007

机译：与急性髓样白血病患者的FLT3内部串联重复相比，FLT3酪氨酸激酶结构域突变在生物学上有所区别，并且预后要好得多。

Acute Myeloid Leukemia Patients with an Activating Mutation in FLT3 Respond to a Small Molecule FLT3 Tyrosine Kinase Inhibitor, PKC412

著录项

相似文献

相关主题

期刊订阅